New Data, New Directions: Bispecific Antibody Advances and CAR T-Cell Evidence in Relapsed/Refractory Multiple Myeloma

In this episode, 'New Data, New Directions: Bispecific Antibody Advances and CAR T-Cell Evidence in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions:

Were there any important updates at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) conferences for bispecific antibodies that will impact your clinical practice?

CAR T-Cell therapy is another modality that can be used in relapsed/refractory multiple myeloma (RRMM) patients. What kind of evidence have these therapies revealed so far?

Zahra Mahmoudjafari highlighted key bispecific antibody updates from ASCO and EHA, including updated data from the MajesTEC-6 trial evaluating elranatamab plus daratumumab and lenalidomide in newly diagnosed patients, and the MajesTEC-5 data demonstrating high response rates and minimal residual disease (MRD) negativity with teclistamab-based induction in transplant-eligible patients, as well as a growing trend toward less frequent dosing schedules to reduce treatment burden and infection risk, and increasing real-world evidence supporting outpatient step-up dosing administration at both academic and community sites. Al-Ola Abdallah then reviewed the CAR T-Cell therapy evidence in RRMM, noting that idecabtagene vicleucel demonstrated a 73% response rate in heavily pretreated triple-refractory patients with a median progression-free survival exceeding one year in the KarMMa study, while ciltacabtagene autoleucel achieved a remarkable 97% response rate and a median progression-free survival of nearly 3 years, ultimately leading to approvals for both agents in earlier lines of therapy given the recognition that patients treated sooner have better fitness and a wider window of eligibility for CAR T-Cell therapy.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Sequencing BCMA Therapies and Identifying the Right Patient: Treatment Selection and Access Considerations in Relapsed/Refractory Multiple Myeloma,' panelists continue their discussion on relapsed/refractory multiple myeloma and highlight how BCMA-targeted therapies should be sequenced, which patient factors inform treatment selection, how the absence of step-up dosing requirements affects the appeal of certain agents, and which patients are and are not appropriate candidates for belantamab mafodotin.